Anastrozole has been evaluated across numerous clinical trials spanning Early Phase 1 through Phase 4 protocols. The majority of these studies focus on early, advanced, invasive, and metastatic breast cancer, alongside non-oncological conditions including metabolic syndrome and inguinal hernia. Led by academic research centers, hospital health networks, and pharmaceutical organizations, these initiatives encompass completed, active not recruiting, recruiting, enrolling by invitation, and terminated protocols.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT07190443 | RECRUITING | Breast Cancer; Locoregional Recurrence; Abemaciclib; Endocrine Therapy |
Japanese Foundation for Cancer Research |
2025-02-07 | PHASE3 |
| NCT05512364 | RECRUITING | ER-positive Breast Cancer; HER2-negative Breast Cancer; Stage IIB Breast Cancer; Stage III Breast Cancer |
European Organisation for Research and Treatment of Cancer - EORTC |
2023-12-15 | PHASE3 |
| NCT06223698 | NOT_YET_RECRUITING | Breast Cancer |
Region Örebro County |
2025-05-02 | PHASE3 |
| NCT07729046 | NOT_YET_RECRUITING | Metastatic Invasive Breast Cancer; Resistant Breast Cancer; ER+, HER2-, Metastatic Breast Cancer |
University of California, San Diego |
2027-07 | PHASE2 |
| NCT07581834 | RECRUITING | Breast Diseases; Breast Neoplasms; Dalpiciclib; Endocrine Breast Diseases; CDK4/6 Inhibitor; HR+/HER2- Breast Cancer |
Fujian Cancer Hospital |
2026-01-21 | PHASE2 |
| NCT07179939 | NOT_YET_RECRUITING | HER2-positive Breast Cancer |
Fudan University |
2025-09-10 | PHASE2 |
| NCT07349069 | RECRUITING | Breast Cancer |
Shandong Suncadia Medicine Co., Ltd. |
2026-03-04 | PHASE3 |
| NCT06671912 | SUSPENDED | Anatomic Stage 0 Breast Cancer AJCC v8; Anatomic Stage 1 Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Estrogen Receptor-Positive Breast Carcinoma; HER2-Negative Breast Carcinoma; Breast Ductal Carcinoma In Situ; Breast Lobular Carcinoma In Situ |
Alliance for Clinical Trials in Oncology |
2025-02-19 | PHASE3 |
| NCT04584853 | ACTIVE_NOT_RECRUITING | Breast Cancer Female |
Institute of Cancer Research, United Kingdom |
2020-12-23 | PHASE3 |
| NCT07716046 | NOT_YET_RECRUITING | Breast Cancer; HER2-positive Breast Cancer; Hormone Receptor-positive Breast Cancer; HR+/HER2+ Breast Cancer |
Fudan University |
2026-10-01 | PHASE2 |
| NCT05768139 | RECRUITING | Breast Cancer; Solid Tumors, Adult |
Eli Lilly and Company |
2023-04-17 | PHASE1; PHASE2 |
| NCT05161195 | ACTIVE_NOT_RECRUITING | Metastatic Breast Cancer |
Novartis Pharmaceuticals |
2022-07-07 | PHASE4 |
| NCT04134598 | ACTIVE_NOT_RECRUITING | Breast Cancer |
Azienda Ospedaliero-Universitaria Careggi |
2021-02-08 | PHASE3 |
| NCT05952557 | ACTIVE_NOT_RECRUITING | Breast Cancer, Early Breast Cancer |
AstraZeneca |
2023-10-05 | PHASE3 |
| NCT05645536 | ENROLLING_BY_INVITATION | Breast Cancer |
Tolmar Inc. |
2022-12-28 | PHASE3 |
| NCT06380751 | RECRUITING | Advanced Breast Cancer |
AstraZeneca |
2024-08-01 | PHASE3 |
| NCT07164976 | RECRUITING | Breast Cancer |
Nagoya City University |
2025-10-01 | PHASE1; PHASE2 |
| NCT06492616 | RECRUITING | Breast Cancer |
Stemline Therapeutics, Inc. |
2024-09-27 | PHASE3 |
| NCT07391774 | RECRUITING | Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Estrogen Receptor-Positive Breast Carcinoma; HER2-Negative Breast Carcinoma |
National Cancer Institute (NCI) |
2026-08-10 | PHASE3 |
| NCT07061717 | NOT_YET_RECRUITING | Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer |
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
2025-07-01 | PHASE3 |
| NCT06507618 | RECRUITING | Breast Cancer Female |
University of Virginia |
2024-07-19 | PHASE3 |
| NCT07174336 | RECRUITING | Breast Neoplasms; Neoplasm Metastasis |
Eli Lilly and Company |
2025-12-22 | PHASE3 |
| NCT05524584 | RECRUITING | Breast Cancer; Metastatic Breast Cancer; Hormone Receptor-positive Breast Cancer; HER2-negative Breast Cancer |
University of California, Irvine |
2022-08-31 | PHASE2 |
| NCT06072781 | RECRUITING | Low Grade Serous Ovarian Cancer |
Verastem, Inc. |
2024-03-18 | PHASE3 |
| NCT06086704 | RECRUITING | Breast Cancer |
University of Wisconsin, Madison |
2024-09-25 | PHASE2 |
| NCT05467891 | RECRUITING | Locoregional Recurrence; Hormone Receptor-positive Breast Cancer; HER2-negative Breast Cancer |
Oana Danciu |
2022-09-13 | PHASE2 |
| NCT07604272 | RECRUITING | Inguinal Hernia Unilateral; Inguinal Hernia Bilateral; Inguinal Hernia Without Obstruction or Gangrene; Inguinal Hernia, Without Mention of Obstruction or Gangrene |
Northwestern University |
2026-07-31 | PHASE1 |
| NCT02942355 | ACTIVE_NOT_RECRUITING | Female Breast Carcinoma; Breast Cancer |
Wake Forest University Health Sciences |
2016-12-07 | PHASE2 |
| NCT02918084 | ACTIVE_NOT_RECRUITING | Breast Cancer |
IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy |
2013-06 | PHASE3 |
| NCT05891093 | RECRUITING | Breast Cancer |
Fudan University |
2023-06-01 | PHASE3 |
| NCT07568574 | ENROLLING_BY_INVITATION | Safety and Impact of Medically Supervised Performance Enhancing Substance Usage in Healthy Elite Athletes |
Enhanced Emirates Limited |
2026-03-12 | |
| NCT05837455 | RECRUITING | Breast Cancer; Cancer of the Breast |
Washington University School of Medicine |
2024-05-30 | PHASE2 |
| NCT05514054 | ACTIVE_NOT_RECRUITING | Breast Neoplasms |
Eli Lilly and Company |
2022-10-04 | PHASE3 |
| NCT04985266 | RECRUITING | ER+ Breast Cancer; HER2-negative Breast Cancer |
Royal Marsden NHS Foundation Trust |
2022-03-30 | PHASE2 |
| NCT03304080 | ACTIVE_NOT_RECRUITING | Breast Neoplasms; Breast Diseases |
Icahn School of Medicine at Mount Sinai |
2017-12-20 | PHASE1; PHASE2 |
| NCT04469764 | RECRUITING | Recurrent Endometrial Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma |
Jonsson Comprehensive Cancer Center |
2020-10-16 | PHASE2 |
| NCT05586802 | RECRUITING | Klinefelter Syndrome |
Georgios Papadakis |
2023-03-21 | PHASE3 |
| NCT05774951 | RECRUITING | Breast Cancer, Early Breast Cancer |
AstraZeneca |
2023-03-31 | PHASE3 |
| NCT05472792 | RECRUITING | Breast Cancer; Quality of Life |
UNC Lineberger Comprehensive Cancer Center |
2022-05-17 | PHASE2 |
| NCT01953588 | ACTIVE_NOT_RECRUITING | Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer |
Alliance for Clinical Trials in Oncology |
2014-02-27 | PHASE3 |
| NCT05501704 | RECRUITING | Male Breast Cancer; Hormone Receptor-positive Breast Cancer; Hormone Receptor Negative Breast Carcinoma |
Jose Pablo Leone |
2023-10-11 | PHASE2 |
| NCT06179303 | RECRUITING | Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Locally Advanced Unresectable HER2-Negative Breast Carcinoma; Locally Advanced Unresectable Hormone Receptor-Positive Breast Carcinoma; Metastatic HER2-Negative Breast Carcinoma; Metastatic Hormone Receptor-Positive Breast Carcinoma |
University of Washington |
2024-07-22 | PHASE2 |
| NCT02476786 | RECRUITING | Breast Cancer; Cancer of Breast; Breast Neoplasms; Cancer of the Breast |
Washington University School of Medicine |
2017-01-17 | PHASE2 |
| NCT07212712 | NOT_YET_RECRUITING | Cerebral Blood Flow; Cerebral Blood Flow Regulation; Sex Differences; Exercise; Vascular |
University of British Columbia |
2026-04-01 | |
| NCT04553770 | RECRUITING | Early-stage Breast Cancer; Hormone Receptor Positive Breast Carcinoma; Invasive Breast Cancer; Stage II Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage III Breast Cancer |
Jonsson Comprehensive Cancer Center |
2020-10-09 | PHASE2 |
| NCT04886531 | RECRUITING | Breast Cancer; HER2-positive Breast Cancer; ER Positive Breast Cancer; PR-Positive Breast Cancer |
Ruth O'Regan |
2022-07-21 | PHASE2 |
| NCT07024173 | RECRUITING | Locally Advanced Breast Cancer; Metastatic Breast Cancer |
Shandong Suncadia Medicine Co., Ltd. |
2025-07-23 | PHASE3 |
| NCT05307705 | RECRUITING | Breast Cancer |
Eli Lilly and Company |
2022-05-11 | PHASE1 |
| NCT07163481 | NOT_YET_RECRUITING | Stage IV (Metastatic) Breast Cancer |
Hunan Cancer Hospital |
2025-10 | PHASE1 |
| NCT05780567 | ACTIVE_NOT_RECRUITING | Breast Cancer |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2023-03-30 | PHASE3 |
| NCT06016738 | ACTIVE_NOT_RECRUITING | Breast Cancer; Advanced Breast Cancer; Metastatic Breast Cancer; ER Positive Breast Cancer; HER2 Negative Breast Carcinoma |
Olema Pharmaceuticals, Inc. |
2023-11-16 | PHASE3 |
| NCT04711252 | ACTIVE_NOT_RECRUITING | ER-Positive HER2-Negative Breast Cancer |
AstraZeneca |
2021-01-28 | PHASE3 |
| NCT05238831 | WITHDRAWN | Advanced Breast Carcinoma; Advanced Malignant Solid Neoplasm; Advanced Ovarian Carcinoma; Advanced Pancreatic Carcinoma; Advanced Prostate Carcinoma; Advanced Sarcoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Recurrent Adult Soft Tissue Sarcoma; Recurrent Breast Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Prostate Carcinoma; Stage II Pancreatic Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8 |
OHSU Knight Cancer Institute |
2023-01-30 | EARLY_PHASE1 |
| NCT04906395 | ACTIVE_NOT_RECRUITING | Breast Cancer |
Tolmar Inc. |
2021-07-01 | PHASE3 |
| NCT05150652 | COMPLETED | Breast Cancer; HER2-negative Breast Cancer; Node-negative Breast Cancer; Breast Carcinoma |
Irada Ibrahim-zada |
2022-02-18 | PHASE2 |
| NCT05257395 | ACTIVE_NOT_RECRUITING | Advanced Breast Cancer |
Xuanzhu Biopharmaceutical Co., Ltd. |
2022-03-14 | PHASE3 |
| NCT06235931 | RECRUITING | Breast Neoplasms |
Second Affiliated Hospital of Soochow University |
2024-02-01 | |
| NCT05190094 | RECRUITING | Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer |
International Cancer Research Group, United Arab Emirates |
2022-12-20 | PHASE2 |
| NCT05896566 | COMPLETED | Breast Cancer |
ETOP IBCSG Partners Foundation |
2024-01-23 | PHASE2 |
| NCT04964934 | ACTIVE_NOT_RECRUITING | ER-Positive HER2-Negative Breast Cancer |
AstraZeneca |
2021-06-30 | PHASE3 |
| NCT06957379 | ACTIVE_NOT_RECRUITING | HR+/HER2- Advanced/Metastatic Breast Cancer |
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. |
2024-02-29 | PHASE2 |
| NCT03490513 | COMPLETED | Hypogonadism, Hypogonadotropic; Obesity |
Baylor College of Medicine |
2018-04-15 | PHASE4 |
| NCT06253702 | COMPLETED | Cerebrovascular Disorders |
University of Wisconsin, Madison |
2024-07-24 | PHASE4 |
| NCT04158362 | ACTIVE_NOT_RECRUITING | Cancer Metastatic |
UNICANCER |
2020-06-11 | PHASE3 |
| NCT04719273 | COMPLETED | Refractory Endometrial Adenocarcinoma; Refractory Endometrial Carcinoma; Refractory Endometrial Clear Cell Adenocarcinoma; Refractory Endometrial Endometrioid Adenocarcinoma; Refractory Endometrial Mixed Cell Adenocarcinoma; Refractory Endometrial Serous Adenocarcinoma; Refractory Endometrial Undifferentiated Carcinoma |
Thomas Jefferson University |
2021-01-28 | PHASE2 |
| NCT02344472 | UNKNOWN | Metastatic Breast Cancer |
Prof. Wolfgang Janni |
2015-09 | PHASE3 |
| NCT04113863 | TERMINATED | Breast Neoplasm Female |
Mario Negri Institute for Pharmacological Research |
2019-06-18 | PHASE2 |
| NCT06001762 | ACTIVE_NOT_RECRUITING | Breast Cancer; Early-stage Breast Cancer; High Risk Breast Carcinoma |
Dana-Farber Cancer Institute |
2023-10-05 | PHASE2 |
| NCT00887380 | UNKNOWN | Breast Cancer |
Trans Tasman Radiation Oncology Group |
2009-09-16 | PHASE3 |
| NCT02947685 | ACTIVE_NOT_RECRUITING | HER-2 Positive Breast Cancer; Estrogen Receptor Positive Breast Cancer |
Alliance Foundation Trials, LLC. |
2017-06-21 | PHASE3 |
| NCT05439499 | UNKNOWN | Advanced Breast Cancer; Female Breast Cancer |
Ahon Pharmaceutical Co., Ltd. |
2022-03-02 | PHASE3 |
| NCT03616587 | ACTIVE_NOT_RECRUITING | ER+ HER2- Advanced Breast Cancer |
AstraZeneca |
2018-10-11 | PHASE1 |
| NCT03909152 | COMPLETED | Granulosa Cell Ovarian Cancer; Low Grade Serous Ovarian/ Primary Peritoneal Cancer; Endometrioid Endometrial Cancer |
Memorial Sloan Kettering Cancer Center |
2019-05-02 | PHASE2 |
| NCT04666961 | RECRUITING | Ductal Carcinoma in Situ; Extensive Disease; Mastectomy |
Institut Cancerologie de l'Ouest |
2021-02-03 | PHASE2 |
| NCT03179904 | COMPLETED | Advanced Breast Carcinoma; HER2-Positive Breast Carcinoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; HER2-positive Breast Cancer |
Mayo Clinic |
2017-08-03 | PHASE2 |
| NCT02095184 | TERMINATED | Breast Cancer |
University of Maryland, Baltimore |
2015-05-25 | |
| NCT02206984 | COMPLETED | Breast Cancer |
Priscilla McAuliffe |
2015-09-30 | PHASE2 |
| NCT05549505 | COMPLETED | Breast Cancer |
Arvinas Inc. |
2023-02-15 | PHASE2 |
| NCT06154590 | Not yet recruiting | Metastatic Breast Cancer|Tumor|Muscle Neoplasms|Chronic Pain |
DR. DIANE CHISESI NFS. MD. PHD.|IRB|Paradyne Networks A Foundation |
2024-07 | -- |
| NCT04272801 | ACTIVE_NOT_RECRUITING | Breast Cancer Female |
Shayna Showalter, MD |
2020-04-07 | PHASE2 |
| NCT02097459 | UNKNOWN | Breast Cancer |
Peking Union Medical College Hospital |
2014-03 | PHASE3 |
| NCT05792410 | UNKNOWN | HER2 Low Advanced or Metastatic Breast Cancer |
Jiangsu HengRui Medicine Co., Ltd. |
2023-04 | PHASE1; PHASE2 |
| NCT02188745 | COMPLETED | Metastatic Breast Cancer |
Dartmouth-Hitchcock Medical Center |
2016-03-11 | PHASE2 |
| NCT03554044 | COMPLETED | Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Estrogen Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage IV Breast Cancer AJCC v8; Recurrent Breast Carcinoma |
University of California, San Francisco |
2020-02-05 | PHASE1 |
| NCT04256941 | TERMINATED | Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Breast Carcinoma; Prognostic Stage IV Breast Cancer AJCC v8 |
M.D. Anderson Cancer Center |
2019-05-31 | PHASE2 |
| NCT04556773 | ACTIVE_NOT_RECRUITING | Metastatic Breast Cancer |
AstraZeneca |
2020-12-17 | PHASE1 |
| NCT04539496 | ACTIVE_NOT_RECRUITING | Metastasis Solid Tumors; Advanced Breast Cancer |
Sihuan Pharmaceutical Holdings Group Ltd. |
2018-05-22 | PHASE1; PHASE2 |
| NCT03099174 | COMPLETED | Neoplasms; Breast Neoplasms |
Boehringer Ingelheim |
2017-05-04 | PHASE1 |
| NCT03238703 | WITHDRAWN | HER2/Neu Negative; Invasive Breast Carcinoma; Postmenopausal; Stage 0 Breast Cancer; Stage IA Breast Cancer |
Fred Hutchinson Cancer Center |
2018-09-01 | PHASE4 |
| NCT04836520 | COMPLETED | Breast Cancer |
Tianjin Medical University Cancer Institute and Hospital |
2021-08-02 | PHASE2 |
| NCT02894398 | COMPLETED | Breast Cancer; Hormone Receptor Positive Tumor; Human Epidermal Growth Factor 2 Negative Carcinoma of Breast |
iOMEDICO AG |
2016-09-06 | PHASE2 |
| NCT01272037 | ACTIVE_NOT_RECRUITING | Breast Ductal Carcinoma In Situ; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma |
National Cancer Institute (NCI) |
2011-02-28 | PHASE3 |
| NCT04707196 | COMPLETED | Breast Neoplasms; Neoplasm Metastasis |
Eli Lilly and Company |
2021-02-22 | PHASE4 |
| NCT04236310 | UNKNOWN | Breast Cancer; HER2-positive Breast Cancer; ER-positive Breast Cancer |
Ruijin Hospital |
2020-01-15 | PHASE2 |
| NCT03966898 | UNKNOWN | Advanced Breast Cancer |
Jiangsu HengRui Medicine Co., Ltd. |
2019-07-19 | PHASE3 |
| NCT04294225 | COMPLETED | Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage IA Breast Cancer AJCC v8; Anatomic Stage IB Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Anatomic Stage IIB Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Early-Stage Breast Carcinoma; Invasive Breast Carcinoma; Prognostic Stage I Breast Cancer AJCC v8; Prognostic Stage IA Breast Cancer AJCC v8; Prognostic Stage IB Breast Cancer AJCC v8; Prognostic Stage II Breast Cancer AJCC v8; Prognostic Stage IIA Breast Cancer AJCC v8; Prognostic Stage IIB Breast Cancer AJCC v8; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8 |
Mayo Clinic |
2020-04-28 | PHASE2 |
| NCT01674140 | ACTIVE_NOT_RECRUITING | Breast Cancer |
SWOG Cancer Research Network |
2013-09-12 | PHASE3 |
| NCT00253422 | COMPLETED | Breast Cancer |
Institute of Cancer Research, United Kingdom |
2004-03-26 | PHASE3 |
| NCT05167643 | UNKNOWN | Advanced HR+ HER2 Negative Breast Carcinoma |
Tianjin Medical University Cancer Institute and Hospital |
2022-01-23 | |
| NCT03691493 | COMPLETED | Anatomic Stage IV Breast Cancer AJCC v8; Estrogen Receptor Positive; HER2/Neu Negative; Metastatic Breast Carcinoma; Metastatic Malignant Neoplasm in the Bone; Progesterone Receptor Positive; Prognostic Stage IV Breast Cancer AJCC v8 |
Emory University |
2019-02-08 | PHASE2 |
| NCT03481998 | COMPLETED | Advanced Breast Cancer |
Jiangsu HengRui Medicine Co., Ltd. |
2018-03-22 | PHASE1; PHASE2 |
| NCT03229499 | COMPLETED | Pulmonary Arterial Hypertension |
University of Pennsylvania |
2017-12-07 | PHASE2 |
| NCT03555877 | COMPLETED | Breast Cancer Metastatic |
GBG Forschungs GmbH |
2018-03-15 | PHASE2 |
| NCT01824836 | ACTIVE_NOT_RECRUITING | Estrogen Receptor-positive Breast Cancer; Musculoskeletal Complications; Progesterone Receptor-positive Breast Cancer; Recurrent Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer |
ECOG-ACRIN Cancer Research Group |
2013-06-11 | |
| NCT00738777 | SUSPENDED | Breast Cancer |
The Netherlands Cancer Institute |
2008-07 | PHASE2 |
| NCT03312738 | COMPLETED | Advanced Breast Cancer |
Novartis Pharmaceuticals |
2017-09-15 | PHASE2 |
| NCT03839823 | COMPLETED | Breast Cancer |
Novartis Pharmaceuticals |
2019-02-25 | PHASE2 |
| NCT02648477 | COMPLETED | Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; Progesterone Receptor Negative; Progesterone Receptor Positive; Stage IV Breast Cancer; Triple-Negative Breast Carcinoma |
City of Hope Medical Center |
2016-03-28 | PHASE2 |
| NCT00301457 | COMPLETED | Breast Cancer |
Maastricht University Medical Center |
2006-06 | PHASE3 |
| NCT03988114 | WITHDRAWN | Metastatic Breast Cancer |
Eli Lilly and Company |
2019-09-16 | PHASE4 |
| NCT04059484 | TERMINATED | Breast Cancer Metastatic |
Sanofi |
2019-10-22 | PHASE2 |
| NCT03220178 | TERMINATED | Breast Neoplasm |
Palleos Healthcare GmbH |
2017-07-24 | PHASE4 |
| NCT02440230 | COMPLETED | Breast Cancer |
Shanghai Jiao Tong University School of Medicine |
2015-05 | PHASE2 |
| NCT04075604 | COMPLETED | Breast Cancer; Cancer |
Bristol-Myers Squibb |
2019-10-18 | PHASE2 |
| NCT04436744 | COMPLETED | Early Breast Cancer |
Hoffmann-La Roche |
2020-09-04 | PHASE2 |
| NCT03822468 | COMPLETED | Breast Cancer |
Novartis Pharmaceuticals |
2019-06-11 | PHASE2 |
| NCT04714619 | Terminated | Advanced Breast Cancer |
MedSIR|Cellestia Biotech AG |
2021-05-06 | Phase 2 |
| NCT01723774 | ACTIVE_NOT_RECRUITING | Breast Neoplasms |
Washington University School of Medicine |
2013-04-10 | PHASE2 |
| NCT02057133 | ACTIVE_NOT_RECRUITING | Breast Neoplasms |
Eli Lilly and Company |
2014-03-10 | PHASE1 |
| NCT04757532 | COMPLETED | Healthy Volunteers |
Parc de Salut Mar |
2020-12-03 | PHASE1 |
| NCT02269670 | TERMINATED | Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Progesterone Receptor-positive Breast Cancer; Recurrent Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer |
Emory University |
2014-11-25 | PHASE2 |
| NCT01197170 | COMPLETED | Solid Tumors; Advanced Cancer |
M.D. Anderson Cancer Center |
2010-09-07 | PHASE1 |
| NCT02109913 | UNKNOWN | Hormone Receptor Positive Malignant Neoplasm of Breast; Metastatic Breast Cancer |
Amsterdam UMC, location VUmc |
2014-03 | |
| NCT03874325 | TERMINATED | Breast Cancer; Hormone Receptor Positive Tumor |
H. Lee Moffitt Cancer Center and Research Institute |
2019-04-26 | PHASE2 |
| NCT04438733 | UNKNOWN | Healthy Volunteers |
The Affiliated Hospital of Qingdao University |
2020-06-18 | PHASE1 |
| NCT04445922 | UNKNOWN | Healthy Volunteers |
The Affiliated Hospital of Qingdao University |
2020-07-04 | PHASE1 |
| NCT03272477 | COMPLETED | Breast Neoplasms |
Palleos Healthcare GmbH |
2017-10-05 | PHASE2 |
| NCT00541086 | UNKNOWN | Breast Cancer |
Gruppo Italiano Mammella (GIM) |
2007-03 | PHASE3 |
| NCT02730091 | TERMINATED | Breast Cancer |
Centre Hospitalier Universitaire de Besancon |
2016-02-24 | PHASE3 |
| NCT03024580 | UNKNOWN | Breast Neoplasm |
Instituto Nacional de Cancer, Brazil |
2017-03-06 | PHASE2 |
| NCT03219476 | COMPLETED | Breast Cancer; Invasive Breast Cancer |
Medical College of Wisconsin |
2017-02-05 | PHASE2 |
| NCT02779751 | ACTIVE_NOT_RECRUITING | Non Small Cell Lung Cancer; Breast Cancer |
Eli Lilly and Company |
2016-11-14 | PHASE1 |
| NCT04227327 | Active not recruiting | Advanced Breast Cancer |
University of Milano Bicocca |
2020-01-07 | Phase 2 |
| NCT02137837 | TERMINATED | Breast Cancer |
SWOG Cancer Research Network |
2014-05 | PHASE3 |
| NCT02730923 | UNKNOWN | Endometrial Carcinoma; Metastatic Carcinoma; Hormone Receptor Positive Tumor |
Centre Leon Berard |
2016-04 | PHASE1; PHASE2 |
| NCT02476955 | TERMINATED | Solid Tumors; Ovarian Cancer; Endometrial Cancer |
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) |
2015-06-09 | PHASE1 |
| NCT02089854 | UNKNOWN | Female Breast Cancer |
Peking Union Medical College Hospital |
2014-11 | PHASE4 |
| NCT02763566 | ACTIVE_NOT_RECRUITING | Breast Cancer |
Eli Lilly and Company |
2016-12-05 | PHASE3 |
| NCT02291913 | COMPLETED | Breast Cancer |
SCRI Development Innovations, LLC |
2014-12-18 | PHASE2 |
| NCT00256217 | COMPLETED | DCIS |
Rita Sanghvi, Mehta |
2004-09-21 | PHASE2 |
| NCT02689921 | UNKNOWN | Breast Neoplasms |
Midwestern Regional Medical Center |
2016-04 | PHASE2 |
| NCT01783444 | COMPLETED | Breast Cancer |
Novartis Pharmaceuticals |
2013-02-26 | PHASE2 |
| NCT02137538 | COMPLETED | Short Stature |
Stanford University |
2009-11-18 | PHASE4 |
| NCT01266213 | UNKNOWN | Metastatic Breast Cancer; Estrogen Receptor Positive Tumor; Breast Cancer Nos Premenopausal |
Samsung Medical Center |
2010-12 | PHASE2 |
| NCT01989780 | COMPLETED | Metastatic Breast Cancer |
Japan Breast Cancer Research Group |
2014-01 | PHASE2 |
| NCT03314298 | COMPLETED | Mammographic Density |
Havah Therapeutics Pty Ltd |
2017-08-14 | PHASE1 |
| NCT03264651 | COMPLETED | Mammographic Density |
Havah Therapeutics Pty Ltd |
2017-02-01 | PHASE1 |
| NCT00310180 | ACTIVE_NOT_RECRUITING | Breast Adenocarcinoma; Hormone Receptor Positive; Stage IA Breast Cancer AJCC v7; Stage IB Breast Cancer AJCC v7; Stage IIA Breast Cancer AJCC v6 and v7; Stage IIB Breast Cancer AJCC v6 and v7; Stage IIIB Breast Cancer AJCC v7 |
National Cancer Institute (NCI) |
2006-04-07 | PHASE3 |
| NCT01216176 | COMPLETED | Breast Cancer |
Joyce Marie Slingerland, MD |
2008-10-21 | PHASE1; PHASE2 |
| NCT01127295 | COMPLETED | Hormono-depending Adjuvant Breast Cancer |
Institut Claudius Regaud |
2010-06-17 | PHASE4 |
| NCT00077168 | UNKNOWN | Breast Cancer |
Institute of Cancer Research, United Kingdom |
2004-04 | PHASE2 |
| NCT02278120 | COMPLETED | Advanced Metastatic Breast Cancer |
Novartis Pharmaceuticals |
2014-11-20 | PHASE3 |
| NCT00295620 | COMPLETED | Breast Cancer |
AstraZeneca |
2004-03-01 | PHASE3 |
| NCT02585388 | TERMINATED | Breast Cancer |
ARCAGY/ GINECO GROUP |
2015-10-23 | PHASE2 |
| NCT01234532 | TERMINATED | Estrogen Receptor-negative Breast Cancer; HER2-negative Breast Cancer; Progesterone Receptor-negative Breast Cancer; Stage I Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Triple-negative Breast Cancer |
University of Maryland, Baltimore |
2010-10 | PHASE2 |
| NCT00437359 | TERMINATED | Breast Neoplasms |
Japan Breast Cancer Research Network |
2007-05 | PHASE2 |
| NCT03933618 | COMPLETED | Hypogonadism, Male |
Albany Medical College |
2015-04-02 | PHASE2 |
| NCT02549430 | COMPLETED | Breast Cancer |
Fondazione Sandro Pitigliani |
2012-10 | PHASE2 |
| NCT02246621 | ACTIVE_NOT_RECRUITING | Breast Cancer |
Eli Lilly and Company |
2014-11-06 | PHASE3 |
| NCT01791985 | COMPLETED | Breast Cancer |
Imperial College London |
2012-07 | PHASE1; PHASE2 |
| NCT02203331 | COMPLETED | Endometriosis |
Bayer |
2014-10-16 | PHASE2 |
| NCT01862835 | COMPLETED | Normal Healthy Volunteers |
Mayo Clinic |
2013-05 | PHASE1 |
| NCT02441946 | COMPLETED | Breast Cancer; Hormone Receptor Positive Tumor; Early-Stage Breast Carcinoma |
Eli Lilly and Company |
2015-08 | PHASE2 |
| NCT01520467 | UNKNOWN | Silver Russell Syndrome; Prader-Willi Syndrome |
Assistance Publique - Hôpitaux de Paris |
2012-04 | |
| NCT00543127 | TERMINATED | Breast Cancer |
Spanish Breast Cancer Research Group |
2007-11 | PHASE3 |
| NCT01602380 | COMPLETED | Hormone Receptor Positive Breast Cancer |
AstraZeneca |
2012-10-17 | PHASE3 |
| NCT02545452 | COMPLETED | Endometriosis |
Bayer |
2015-09-15 | PHASE1 |
| NCT02269072 | WITHDRAWN | Hypertension |
Massachusetts General Hospital |
2015-02 | |
| NCT01763541 | WITHDRAWN | Hypertension |
Massachusetts General Hospital |
2014-06 | EARLY_PHASE1 |
| NCT01612871 | COMPLETED | Breast Cancer |
Institut Claudius Regaud |
2012-06-27 | PHASE4 |
| NCT01597193 | COMPLETED | Breast Cancer |
Pfizer |
2012-04-30 | PHASE1 |
| NCT00072462 | COMPLETED | Breast Cancer |
Queen Mary University of London |
2003-09 | PHASE3 |
| NCT02140437 | WITHDRAWN | Carcinoma Breast Stage IV |
Fudan University |
2014-03 | PHASE2 |
| NCT02026973 | COMPLETED | Normal Healthy Volunteers |
Mayo Clinic |
2014-03 | PHASE1 |
| NCT02000596 | TERMINATED | Metastatic Breast Cancer |
University of Maryland, Baltimore |
2014-01 | PHASE2 |
| NCT02072512 | UNKNOWN | Metastatic Breast Cancer |
Hospital Affiliated to Military Medical Science, Beijing |
2014-01 | PHASE2 |
| NCT00629616 | COMPLETED | Breast Cancer |
UNICANCER |
2007-10 | PHASE2 |
| NCT01545336 | COMPLETED | Pulmonary Arterial Hypertension |
University of Pennsylvania |
2012-10 | PHASE2 |
| NCT00661531 | TERMINATED | Breast Cancer; Cancer of the Breast; Neoplasms, Breast |
Georgetown University |
2008-04 | PHASE2 |
| NCT01776008 | TERMINATED | Estrogen Receptor Positive; HER2/Neu Negative; Recurrent Breast Carcinoma; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer |
National Cancer Institute (NCI) |
2013-01 | PHASE2 |
| NCT02093351 | COMPLETED | Solid Tumours |
AstraZeneca |
2014-09-01 | PHASE1 |
| NCT00921115 | COMPLETED | Invasive Breast Cancer |
University of Kansas Medical Center |
2009-05 | PHASE2 |
| NCT01720602 | COMPLETED | Male Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer |
University of Washington |
2012-11 | |
| NCT00053898 | COMPLETED | Breast Cancer |
NSABP Foundation Inc |
2003-01 | PHASE3 |
| NCT00863655 | COMPLETED | Breast Cancer |
Novartis Pharmaceuticals |
2009-06-03 | PHASE3 |
| NCT00248170 | COMPLETED | Breast Cancer |
Novartis Pharmaceuticals |
2005-12 | PHASE3 |
| NCT01972984 | COMPLETED | Breast Cancer |
Ottawa Hospital Research Institute |
2012-10 | PHASE2 |
| NCT01381874 | COMPLETED | Metastatic ER+ Her2- Breast Cancer; Postmenopausal |
Janssen Research & Development, LLC |
2011-08-24 | PHASE2 |
| NCT00440180 | TERMINATED | Obesity; Oligospermia |
University of Utah |
2007-03 | PHASE3 |
| NCT00104572 | COMPLETED | Hypogonadism; Diabetes; Sarcopenia; Osteoporosis; Depression |
National Institute on Aging (NIA) |
2004-03 | PHASE2 |
| NCT00078832 | COMPLETED | Breast Cancer |
Queen Mary University of London |
2003-09 | PHASE3 |
| NCT00871858 | COMPLETED | Breast Cancer |
Institut Bergonié |
2008-03-18 | PHASE2 |
| NCT01262274 | TERMINATED | Breast Neoplasms |
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan |
2010-12 | PHASE2 |
| NCT00077025 | COMPLETED | Breast Cancer |
AstraZeneca |
2004-01 | PHASE2 |
| NCT01280045 | TERMINATED | UTERINE LEIOMYOMA |
University of Sao Paulo |
2011-01 | |
| NCT01368263 | TERMINATED | Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer |
Washington University School of Medicine |
2011-09 | PHASE2 |
| NCT01553903 | COMPLETED | Breast Cancer |
Institut Claudius Regaud |
2011-12 | PHASE4 |
| NCT00688194 | UNKNOWN | Breast Cancer |
Gruppo Italiano Mammella (GIM) |
2008-05 | PHASE3 |
| NCT00186121 | COMPLETED | Breast Cancer |
Stanford University |
2000-10 | PHASE2 |
| NCT00573755 | TERMINATED | Breast Cancer |
Mayo Clinic |
2007-12 | PHASE2 |
| NCT00122356 | COMPLETED | Breast Cancer |
Barwon Health |
2005-09 | PHASE3 |
| NCT00932152 | TERMINATED | Non-small Cell Lung Cancer; Postmenopausal Women |
University of Pittsburgh |
2010-09 | PHASE2 |
| NCT01151215 | TERMINATED | Neoplasms; Breast Neoplasms; Breast Cancer |
AstraZeneca |
2010-06 | PHASE2 |
| NCT00075764 | COMPLETED | Breast Cancer |
SWOG Cancer Research Network |
2004-04 | PHASE3 |
| NCT01231659 | COMPLETED | Postmenopausal Women; Locally Advanced Metastatic Breast Cancer; Metastatic Breast Cancer |
Novartis Pharmaceuticals |
2011-08-09 | PHASE2 |
| NCT00265759 | COMPLETED | Breast Cancer |
Alliance for Clinical Trials in Oncology |
2006-01 | PHASE3 |
| NCT01153672 | COMPLETED | Male Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer |
University of Washington |
2010-11 | |
| NCT01568281 | COMPLETED | Safety; Pharmacokinetics |
AstraZeneca |
2012-04 | PHASE1 |
| NCT00057941 | COMPLETED | Estrogen Receptor-positive Breast Cancer; Progesterone Receptor-positive Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer |
National Cancer Institute (NCI) |
2003-09 | PHASE2 |
| NCT00684216 | TERMINATED | Breast Cancer |
The Netherlands Cancer Institute |
2008-04 | PHASE2; PHASE3 |
| NCT01394211 | TERMINATED | Estrogen Receptor-positive Breast Cancer; Human Epidermal Growth Factor 2 Negative Carcinoma of Breast; Male Breast Cancer; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer |
University of Arizona |
2011-07-13 | PHASE2 |
| NCT00893061 | COMPLETED | Breast Cancer |
Centre Oscar Lambret |
2009-03-16 | PHASE3 |
| NCT01215292 | COMPLETED | Healthy Males |
University of Washington |
2011-01 | PHASE1; PHASE2 |
| NCT00728949 | COMPLETED | Metastatic Breast Cancer |
Eli Lilly and Company |
2008-08 | PHASE2 |
| NCT00537771 | COMPLETED | Breast Cancer |
AstraZeneca |
2007-09 | PHASE4 |
| NCT00555477 | TERMINATED | Breast Cancer |
University of Michigan Rogel Cancer Center |
2007-08 | PHASE2 |
| NCT01344031 | COMPLETED | Estrogen Receptor Positive; Invasive Breast Carcinoma; Recurrent Breast Carcinoma; Stage IV Breast Cancer AJCC v6 and v7 |
National Cancer Institute (NCI) |
2011-04-21 | PHASE1 |
| NCT00944918 | COMPLETED | Progression-free Survival |
AstraZeneca |
2008-12 | PHASE3 |
| NCT00354302 | COMPLETED | Breast Cancer; Osteoporosis |
NCIC Clinical Trials Group |
2006-04-24 | PHASE3 |
| NCT00433173 | SUSPENDED | Metabolic Syndrome |
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
2006-05 | |
| NCT00612560 | COMPLETED | Breast Cancer |
Roswell Park Cancer Institute |
2007-11 | |
| NCT00143390 | COMPLETED | Breast Neoplasms |
Pfizer |
2005-04 | PHASE3 |
| NCT00066573 | COMPLETED | Breast Cancer |
NCIC Clinical Trials Group |
2003-06-06 | PHASE3 |
| NCT03118479 | TERMINATED | Hypogonadotropic Hypogonadism; Kallmann Syndrome |
Massachusetts General Hospital |
2010-05 | PHASE1 |
| NCT00519883 | UNKNOWN | Musculoskeletal Symptoms |
British Columbia Cancer Agency |
2007-12 | PHASE3 |
| NCT00405938 | COMPLETED | Breast Cancer; Breast Neoplasms |
SCRI Development Innovations, LLC |
2006-11 | PHASE2 |
| NCT00902954 | UNKNOWN | Breast Cancer |
Fudan University |
2008-03 | PHASE3 |
| NCT00729859 | COMPLETED | Healthy |
University of Washington |
2008-12 | PHASE2 |
| NCT00687648 | UNKNOWN | Breast Cancer |
National Cancer Centre, Singapore |
2008-05 | PHASE2 |
| NCT00438321 | TERMINATED | Metabolic Syndrome |
Massachusetts General Hospital |
2006-09 | PHASE1 |
| NCT00481845 | TERMINATED | Breast Cancer |
Stanford University |
2008-01 | PHASE2 |
| NCT00588003 | COMPLETED | Breast Cancer |
Memorial Sloan Kettering Cancer Center |
2004-03 | PHASE1 |
| NCT00605267 | COMPLETED | Breast Cancer |
AstraZeneca |
2007-10 | PHASE3 |
| NCT00263185 | COMPLETED | Breast Neoplasms |
Washington University School of Medicine |
2005-11 | EARLY_PHASE1 |
| NCT01004744 | COMPLETED | Invasive Breast Cancer |
Columbia University |
2007-07 | |
| NCT00217399 | COMPLETED | Recurrent Breast Cancer; Stage IV Breast Cancer |
National Cancer Institute (NCI) |
2005-06 | PHASE1; PHASE2 |
| NCT00688909 | COMPLETED | Breast Cancer |
Novartis Pharmaceuticals |
2008-03 | PHASE4 |
| NCT00291759 | COMPLETED | Breast Cancer |
AstraZeneca |
1996-01 | PHASE3 |
| NCT00081510 | COMPLETED | Breast Cancer |
Merck Sharp & Dohme LLC |
2003-12 | PHASE2 |
| NCT00256698 | COMPLETED | Breast Cancer |
AstraZeneca |
2004-01 | PHASE3 |
| NCT00323479 | COMPLETED | Early Breast Cancer |
AstraZeneca |
2006-06 | PHASE4 |
| NCT00354640 | COMPLETED | Breast Cancer |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2006-06 | PHASE2 |
| NCT00357110 | COMPLETED | Breast Cancer |
AstraZeneca |
2006-04 | PHASE2 |
| NCT00259090 | COMPLETED | Breast Cancer |
AstraZeneca |
2004-04 | PHASE2 |
| NCT00136695 | COMPLETED | Hypogonadism |
Massachusetts General Hospital |
2004-10 | PHASE2 |
| NCT01105299 | COMPLETED | Healthy |
Asan Medical Center |
2008-06 | |
| NCT01155960 | COMPLETED | Healthy |
Dr. Reddy's Laboratories Limited |
2008-05 | PHASE1 |
| NCT01155947 | COMPLETED | Healthy |
Dr. Reddy's Laboratories Limited |
2008-05 | PHASE1 |
| NCT00094328 | COMPLETED | Puberty, Precocious |
AstraZeneca |
2004-11-22 | PHASE2 |
| NCT00179517 | COMPLETED | Seizure Disorder; Hypogonadism; Erectile Dysfunction |
Beth Israel Deaconess Medical Center |
2001-06 | PHASE2 |
| NCT00295646 | COMPLETED | Breast Cancer |
Austrian Breast & Colorectal Cancer Study Group |
1999-06 | PHASE3 |
| NCT00274469 | COMPLETED | Metastatic Breast Cancer |
AstraZeneca |
2006-02-06 | PHASE2 |
| NCT00005908 | COMPLETED | Breast Cancer; Breast Neoplasm |
National Cancer Institute (NCI) |
2000-06 | PHASE2 |
| NCT00329940 | COMPLETED | Breast Cancer |
Novartis Pharmaceuticals |
2005-11 | PHASE3 |
| NCT00213148 | COMPLETED | Anovulation |
EMD Serono |
2005-03-10 | PHASE2 |
| NCT00544986 | COMPLETED | Breast Cancer |
AstraZeneca |
2005-06 | PHASE4 |
| NCT00049062 | COMPLETED | Breast Cancer |
The University of Texas Health Science Center at San Antonio |
2002-09 | PHASE2 |
| NCT00082277 | COMPLETED | Breast Cancer |
AstraZeneca |
2004-04 | PHASE4 |
| NCT00244959 | COMPLETED | Breast Cancer |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2004-01 | PHASE2 |
| NCT00467493 | COMPLETED | Menstruation Disorders |
Meditrina Pharmaceuticals |
2007-03 | PHASE2 |
| NCT00066378 | COMPLETED | Breast Cancer |
European Organisation for Research and Treatment of Cancer - EORTC |
2003-05 | PHASE2 |
| NCT01016665 | COMPLETED | Breast Cancer |
Federal University of São Paulo |
2005-04 | |
| NCT00303615 | TERMINATED | Metastatic Breast Cancer |
Legacy Health System |
2005-06 | PHASE2 |
| NCT00217659 | WITHDRAWN | Breast Cancer |
SWOG Cancer Research Network |
2005-09 | PHASE2 |
| NCT00241436 | COMPLETED | Gynecomastia |
AstraZeneca |
2005-06 | PHASE2 |
| NCT00133354 | COMPLETED | Hypopituitarism |
Nemours Children's Clinic |
2001-11 | PHASE2; PHASE3 |
| NCT01155089 | COMPLETED | Breast Cancer |
Roxane Laboratories |
2006-05 | |
| NCT01155102 | COMPLETED | Breast Cancer |
Roxane Laboratories |
2006-04 | |
| NCT00181688 | COMPLETED | Ovarian Cancer; Peritoneal Carcinoma; Tubal Carcinoma |
Massachusetts General Hospital |
2003-10 | PHASE2 |
| NCT00055302 | COMPLETED | McCune-Albright Syndrome |
AstraZeneca |
2002-08 | PHASE2 |
| NCT01183390 | COMPLETED | Healthy |
Teva Pharmaceuticals USA |
2005-09 | PHASE1 |
| NCT01182181 | COMPLETED | Healthy |
Teva Pharmaceuticals USA |
2005-08 | PHASE1 |
| NCT00128843 | COMPLETED | Breast Cancer |
Spanish Breast Cancer Research Group |
2001-08 | PHASE2 |
| NCT00784940 | COMPLETED | Bone Density |
AstraZeneca |
1998-06 | PHASE3 |
| NCT00053911 | TERMINATED | Breast Cancer |
UNICANCER |
2002-11 | PHASE3 |
| NCT00066339 | COMPLETED | Breast Cancer |
European Organisation for Research and Treatment of Cancer - EORTC |
2003-05 | PHASE2 |
| NCT00637182 | COMPLETED | Gynecomastia |
AstraZeneca |
2001-01 | PHASE3 |
| NCT00814125 | COMPLETED | Breast Cancer |
AstraZeneca |
1997-06 | PHASE3 |
| NCT00004900 | COMPLETED | Breast Cancer |
Hackensack Meridian Health |
1999-10 | PHASE2 |
| NCT00004906 | COMPLETED | Breast Cancer |
Hackensack Meridian Health |
1999-10 | PHASE2 |
| NCT00382057 | WITHDRAWN | Metabolic Syndrome |
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
2006-05 | PHASE2 |
| NCT00437853 | COMPLETED | Breast Cancer |
Instituto Nacional de Cancerologia de Mexico |
2003-06 | |
| NCT00327769 | COMPLETED | Advanced Breast Cancer |
AstraZeneca |
2005-11 | PHASE3 |
| NCT00784862 | COMPLETED | Breast Cancer |
AstraZeneca |
1998-06 | PHASE3 |
| NCT00126360 | UNKNOWN | Breast Cancer |
St George Hospital, Australia |
2005-08 | PHASE4 |
| NCT00235937 | COMPLETED | Breast Cancer |
AstraZeneca |
2001-12 | PHASE2 |
| NCT00255463 | COMPLETED | Breast Cancer |
AstraZeneca |
2004-01 | PHASE2 |
| NCT00398489 | UNKNOWN | Breast Cancer |
Technical University of Munich |
2006-10 | PHASE2 |
| NCT00300508 | COMPLETED | Breast Neoplasms |
AstraZeneca |
1996-01 | PHASE3 |
| NCT00635713 | COMPLETED | Advanced Breast Cancer |
AstraZeneca |
1997-05 | PHASE3 |
| NCT00287534 | COMPLETED | Breast Cancer |
AstraZeneca |
1996-11 | PHASE2 |
| NCT00324714 | WITHDRAWN | Breast Cancer; Osteoporosis |
ETOP IBCSG Partners Foundation |
2003-02 | PHASE3 |
| NCT00784680 | COMPLETED | Quality of Life |
AstraZeneca |
1998-04 | PHASE3 |
| NCT00286117 | COMPLETED | Breast Cancer |
AstraZeneca |
1998-03 | PHASE3 |
(data from https://clinicaltrials.gov, updated on 2025-09-29)
Check the
Anastrozole
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
Note: Technical data last updated: Sep 1, 2026.